natgillin/translations-raw huggingface dataset:
The doctor will work out the right dose of granules for oral suspension based on the age and weight of the infant or toddler.
Liječnik će izračunati točnu dozu granula za oralnu suspenziju na temelju dobi i tjelesne težine dojenčeta ili maloga djeteta.
• stomach inflammation
• upalu želuca
You should check with your child's doctor, pharmacist or nurse if you are not sure.
Provjerite s djetetovim liječnikom, ljekarnikom ili medicinskom sestrom ako niste sigurni.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination anti-retroviral therapy and should be monitored according to standard practice.
U bolesnika s već postojećom disfunkcijom jetre, uključujući kronični hepatitis, su tijekom kombinirane antiretrovirusne terapije učestaliji poremećaji jetrene funkcije te ih stoga treba nadzirati u skladu sa standardnom praksom.
The most frequently reported serious adverse reactions were immune reconstitution syndrome and rash.
Najčešće prijavljivane ozbiljne nuspojave bile su sindrom imunološke rekonstitucije i osip.
Do not pour it into the sink.
Nemojte ga izliti u sudoper.
Strong inducers of drug metabolizing enzymes
Snažni induktori enzima koji sudjeluju u metabolizmu lijekova
Excipients with known effect 100 mg
Pomoćne tvari s poznatim učinkom za 100 mg
The safety profile observed in patients who used atazanavir and / or tenofovir disoproxil fumarate was generally similar to the safety profile of patients who did not use these agents.
Sigurnosni profil lijeka opažen u bolesnika koji su primali atazanavir i/ili tenofovirdizoproksilfumarat bio je općenito sličan onomu u bolesnika koji nisu uzimali ove lijekove.
Depression, including suicidal ideation and behaviours, has been reported, particularly in patients with a pre-existing history of depression or psychiatric illness.
Prijavljena je depresija, uključujući suicidalne ideacije i ponašanja, osobito u bolesnika s depresijom ili psihijatrijskom bolešću u anamnezi.
Mix Isentress and water
7. korak: Promiješajte Isentress i vodu
Maximum dose of oral suspension is 100 mg twice daily.
Najviša doza oralne suspenzije je 100 mg dvaput na dan.
For each of the following clinical adverse reactions there was at least one serious occurrence: genital herpes, anaemia, immune reconstitution syndrome, depression, mental disorder, suicide attempt, gastritis, hepatitis, renal failure, accidental overdose.
Zabilježen je najmanje jedan ozbiljan slučaj za svaku od sljedećih kliničkih nuspojava: genitalni herpes, anemiju, sindrom imunološke rekonstitucije, depresiju, mentalni poremećaj, pokušaj suicida, gastritis, hepatitis, zatajenje bubrega, slučajno predoziranje.
3 to less than 4 2.5 mL (25 mg) twice daily 4 to less than 6 3 mL (30 mg) twice daily 6 to less than 8 4 mL (40 mg) twice daily 8 to less than 11 6 mL (60 mg) twice daily 11 to less than 14
Broj tableta za žvakanje od 3 do manje od 4 2,5 ml (25 mg) dvaput na dan od 4 do manje od 6 3 ml (30 mg) dvaput na dan od 6 do manje od 8 4 ml (40 mg) dvaput na dan od 8 do manje od 11 6 ml (60 mg) dvaput na dan od 11 do manje od 14
In faeces, only raltegravir was present, most of which is likely to be derived from hydrolysis of raltegravir-glucuronide secreted in bile as observed in preclinical species.
U fecesu je prisutan samo raltegravir, a njegov je veći dio vjerojatno nastao hidrolizom raltegravir-glukuronida izlučenog u žuči, kao što je opaženo u nekliničkim ispitivanjima na životinjama.
The dose should be administered orally within 30 minutes of mixing.
Doza se mora primijeniti kroz usta unutar 30 minuta od pripreme (miješanja).
ISENTRESS should be used in combination with other active anti-retroviral therapies (ARTs) (see sections 4.4 and 5.1).
ISENTRESS se mora primjenjivati u kombinaciji s drugom aktivnom antiretrovirusnom terapijom (ART) (vidjeti dijelove 4.4 i 5.1).
One pack size is available: 1 bottle with 60 tablets.
Dostupna je jedna veličina pakiranja: 1 boca sa 60 tableta.
What Isentress contains
Što Isentress sadrži
Raltegravir is an integrase strand transfer inhibitor active against the Human Immunodeficiency Virus (HIV-1).
Raltegravir je inhibitor prijenosa lanca integraze, aktivan protiv virusa humane imunodeficijencije (HIV-1).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination anti-retroviral therapy.
Iako se smatra da ima više uzroka (uključujući primjenu kortikosteroida, konzumiranje alkohola, jaku imunosupresiju, povišen indeks tjelesne mase), slučajevi osteonekroze bili su prijavljeni posebice u bolesnika s uznapredovalom HIV bolešću i/ili u bolesnika izloženih dugotrajnoj kombiniranoj antiretrovirusnoj terapiji (engl. combination anti-retroviral therapy, CART).
Because the extent to which raltegravir may be dialysable is unknown, dosing before a dialysis session should be avoided.
S obzirom da nije poznato u kojoj se mjeri raltegravir može ukloniti dijalizom, treba izbjegavati doziranje prije dijalize.
Raltegravir 600 mg tablets (2 x 600 mg once daily) may be administered with or without food.
Raltegravir tablete od 600 mg (2 x 600 mg jedanput na dan) mogu se primjenjivati s hranom ili bez nje.
ISENTRESS 600 mg film-coated tablet formulation should not be used in children weighing less than 40 kg.
ISENTRESS 600 mg filmom obložene tablete ne smiju se primjenjivati u djece tjelesne težine manje od 40 kg.
Excipients with known effect Each sachet contains approximately: 0.5 mg fructose, 1.5 mg sorbitol and 4.7 mg sucrose.
Pomoćne tvari s poznatim učinkom Jedna vrećica sadrži približno: 0,5 mg fruktoze, 1,5 mg sorbitola i 4,7 mg saharoze.
Be sure to keep your doctor's appointments so you always know how much Isentress to give.
Obavezno idite na sve liječničke preglede kako biste uvijek znali koliko lijeka Isentress trebate dati djetetu.
In two studies of HIV-1 infected patients who received raltegravir 400 mg twice daily, raltegravir was readily detected in the cerebrospinal fluid.
U dva ispitivanja u bolesnika inficiranih virusom HIV-1 koji su primali raltegravir u dozi od 400 mg, dvaput na dan raltegravir je bio detektiran u cerebrospinalnoj tekućini.
Detailed information on this medicine is available on the European Medicines Agency web site:http://www.ema.europa.eu.
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
Following reconstitution the oral suspension has a concentration of 10 mg per mL.
Nakon rekonstitucije, koncentracija oralne suspenzije iznosi 10 mg/ml.
The safety and efficacy of raltegravir have not been established in patients with severe underlying liver disorders.
Sigurnost i djelotvornost raltegravira u bolesnika s postojećim teškim poremećajima jetrene funkcije nisu ustanovljene.
IMPAACT P1110 is a Phase I trial to evaluate the safety and pharmacokinetics of raltegravir granules for suspension (GFS) with standard care PMTCT in full term HIV-1-exposed neonates.
Ispitivanje IMPAACT P1110 bilo je ispitivanje faze I provedeno radi ocjene sigurnosti i farmakokinetike raltegravir granula za suspenziju uz standardnu terapiju za PMTCT u terminske novorođenčadi izložene virusu HIV-1.
Given that raltegravir is metabolised primarily via UGT1A1, caution should be used when co-administering raltegravir with strong inducers of UGT1A1 (e.g., rifampicin).
Obzirom da se raltegravir primarno metabolizira putem UGT1A1 potreban je oprez kada se raltegravir primjenjuje istodobno sa snažnim induktorima UGT1A1 (npr. rifampicinom).
Pink, oval tablet, marked with "227" on one side.
Ružičasta, ovalna tableta s oznakom "227" na jednoj strani.
ISENTRESS 400 mg tablets can be administered with or without food.
ISENTRESS 400 mg tablete mogu se primjenjivati s hranom ili bez nje.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
Ako ste roditelj djeteta koje uzima lijek Isentress, pažljivo pročitajte cijelu uputu zajedno s djetetom.
• There will usually be some leftover, prepared Isentress in the mixing cup.
• Obično u čaši za miješanje preostane određena količina pripremljenog lijeka Isentress.
Note: The chewable tablets are available as 25 mg and 100 mg tablets.
Napomena: Tablete za žvakanje dostupne su kao tablete od 25 mg i 100 mg.
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account in order to characterise the safety for the foetus.
Općenito je pravilo, kada se odlučuje o primjeni antiretrovirusnih lijekova za liječenje HIV infekcije u trudnica te, posljedično, za smanjenje rizika od vertikalnog prijenosa HIV-a na novorođenče, da se moraju uzeti u obzir podaci iz ispitivanja na životinjama, kao i kliničko iskustvo primjene u trudnica kako bi se mogla odrediti sigurnost za fetus.
This neoplasia could result from local deposition and/or aspiration of drug on the mucosa of the nose/nasopharynx during oral gavage dosing and subsequent chronic irritation and inflammation; it is likely that it is of limited relevance for the intended clinical use.
Te su novotvorine mogle nastati zbog aspiracije i/ili lokalnog nakupljanja lijeka na sluznici nosa/nazofarinksa tijekom izravne primjene lijeka putem sonde i posljedične kronične iritacije i upale.
The recommended dosage for paediatric patients of at least 25 kg body weight is 400 mg (one tablet) twice daily.
Preporučena doza za pedijatrijske bolesnike čija je tjelesna težina najmanje 25 kg je 400 mg (jedna tableta) dvaput na dan.
Excipients with known effect 25 mg
Pomoćne tvari s poznatim učinkom za 25 mg
The doctor will work out the right dose of the chewable tablet based on the age and weight of the child.
Liječnik će izračunati točnu dozu tableta za žvakanje na temelju dobi i tjelesne težine djeteta.
White to off-white, granular powder that may contain yellow or beige to tan particles, in a single-use sachet.
Bijeli do bjelkasti granulirani prašak koji može sadržavati čestice žute ili bež do svijetlosmeđe boje, u vrećici za jednokratnu primjenu.
Raltegravir should not be used during breast-feeding.
Raltegravir se ne smije primjenjivati tijekom dojenja.
A further 531 treatment-naïve adults have received raltegravir 1,200 mg once daily with emtricitabine and tenofovir disoproxil fumarate for up to 96 weeks.
Osim toga, 531 prethodno neliječeni odrasli bolesnik primao je raltegravir u dozi od 1200 mg jedanput na dan u kombinaciji s emtricitabinom i tenofovirdizoproksilfumaratom do 96 tjedana.
ISENTRESS granules for oral suspension contain fructose, sorbitol and sucrose.
ISENTRESS granule za oralnu suspenziju sadrže fruktozu, sorbitol i saharozu.
In randomised clinical trials raltegravir 400 mg twice daily was administered in combination with fixed or optimised background treatment regimens to treatment-naïve (N=547) and treatmentexperienced (N=462) adults for up to 96 weeks.
U randomiziranim kliničkim ispitivanjima raltegravir u dozi od 400 mg dvaput na dan primjenjivao se u kombinaciji s fiksnim ili optimiziranim osnovnim režimom liječenja u prethodno neliječenih (N=547) i prethodno liječenih (N=462) odraslih bolesnika do 96 tjedana.
ISENTRESS 600 mg tablets can be administered with or without food as a 1,200 mg once daily dose.
ISENTRESS 600 mg tablete mogu se primjenjivati s hranom ili bez nje u dozi od 1200 mg jedanput na dan.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take:
Obavijestite liječnika, ljekarnika ili medicinsku sestru ako uzimate ili ste nedavno uzeli ili biste mogli uzeti:
There were no drug related clinical adverse experiences and three drug-related laboratory adverse experiences (one a transient Grade 4 neutropenia in a subject receiving zidovudine containing prevention of mother to child transmission (PMTCT), and two bilirubin elevations (one each, Grade 1 and Grade 2) considered non-serious and not requiring specific therapy).
Nije bilo kliničkih štetnih događaja povezanih s primjenom lijeka, ali su zabilježena tri laboratorijska štetna događaja povezana s primjenom lijeka (jedan slučaj prolazne neutropenije 4. stupnja u ispitanika koji je primao terapiju za prevenciju prijenosa infekcije s majke na dijete [engl. prevention of mother to child transmission, PMTCT] koja je sadržavala zidovudin, i dva slučaja povišenih vrijednosti bilirubina [jedan slučaj 1. stupnja i jedan slučaj 2. stupnja], koja se nisu smatrala ozbiljnima i nisu zahtijevala specifičnu terapiju).
• infection of the hair roots; influenza; skin infection due to virus; vomiting or diarrhoea due to an infectious agent; upper respiratory tract infection; lymph node abscess
• infekcija korijena dlake; gripa; kožne infekcije uzrokovane virusom; povraćanje ili proljev zbog infekcije; infekcija gornjih dišnih puteva; apsces limfnih čvorova
The effect of food on the granules for oral suspension formulation was not studied.
Nije ispitivan učinak hrane na lijek u obliku granula za oralnu suspenziju.
Patients co-infected with hepatitis B and/or hepatitis C virus In clinical trials, there were 79 patients co-infected with hepatitis B, 84 co-infected with hepatitis C, and 8 patients co-infected with hepatitis B and C who were treated with raltegravir in combination with other agents for HIV-1.
Bolesnici koji su istodobno inficirani virusom hepatitisa B i/ili hepatitisa C U kliničkim je ispitivanjima sudjelovalo 79 bolesnika istodobno inficiranih virusom hepatitisa B, 84 bolesnika istodobno inficirana virusom hepatitisa C i 8 bolesnika istodobno inficiranih virusom hepatitisa B i C koji su liječeni raltegravirom u kombinaciji s drugim lijekovima za HIV-1.
For patients weighing between 11 and 20 kg, either the granules for oral suspension or the chewable tablet can be used as specified in Table 1 (see section 5.2).
Za bolesnike tjelesne težine između 11 i 20 kg mogu se primijeniti ili granule za oralnu suspenziju ili tablete za žvakanje, kako je prikazano u Tablici 1 (vidjeti dio 5.2).
Raltegravir was administered as granules for oral suspension formulation without regard to food in combination with an optimised background regimen that included lopinavir plus ritonavir in two-thirds of patients.
Raltegravir se primjenjivao u obliku granula za oralnu suspenziju, neovisno o hrani, u kombinaciji s optimiziranom osnovnom terapijom koja je u dvije trećine bolesnika uključivala lopinavir + ritonavir.
Children at least 11 kg: weight based dose of the chewable tablet to a maximum dose of 300 mg, twice daily as specified in Tables 1 and 2.
Djeca tjelesne težine najmanje 11 kg: doza tableta za žvakanje određuje se na temelju tjelesne težine do najviše doze od 300 mg dvaput na dan, kako je prikazano u Tablicama 1 i 2.
Mental health problems
Tegobe s mentalnim zdravljem
Rifampicin reduces plasma levels of raltegravir.
Rifampicin snižava razine raltegravira u plazmi.
There are no data for the use of raltegravir chewable tablets in pregnant women.
Nema podataka o primjeni raltegravir tableta za žvakanje u trudnica.
Less potent UGT1A1 inhibitors (e.g., indinavir, saquinavir) may also increase plasma levels of raltegravir, but to a lesser extent compared with atazanavir.
Manje potentni inhibitori UGT1A1 (npr. indinavir, sakvinavir) mogu također povisiti koncentraciju raltegravira u plazmi, no u manjoj mjeri nego atanazavir.
There is limited information regarding the use of raltegravir in the elderly (see section 5.2).
Podaci o primjeni raltegravira u starijih osoba su ograničeni (vidjeti dio 5.2).
> 50 and ≤ 200 cells/mm
> 50 i ≤ 200 stanica/mm
What you need to know before you take Isentress
Što morate znati prije nego počnete uzimati Isentress
Pour the leftover prepared Isentress into the rubbish.
Izlijte preostali pripremljeni lijek Isentress u kantu za otpad.
• rifampicin (a medicine used to treat some infections such as tuberculosis), as it may decrease your levels of Isentress.
• rifampicin (lijek za liječenje nekih zaraznih bolesti poput tuberkuloze), jer on može sniziti koncentraciju lijeka Isentress u Vašem tijelu.
Population pharmacokinetic analysis from ONCEMRK (Protocol 292) showed that co-administration of raltegravir 1,200 mg once daily with PPIs or H2 blockers did not result in statistically significant changes in the pharmacokinetics of raltegravir.
Populacijska farmakokinetička analiza provedena u ispitivanju ONCEMRK (Protokol 292) pokazala je da istodobna primjena raltegravira u dozi od 1200 mg jedanput na dan s inhibitorima protonske pumpe ili blokatorima H2-receptora nije dovela do statistički značajnih promjena farmakokinetike raltegravira.
The tablet can be divided into equal 50 mg doses.
Tableta se može podijeliti na jednake doze od 50 mg.
Birth to 1 Week - Once daily dosing
Od rođenja do dobi od 1 tjedna - primjena jedanput na dan od 2 do manje od 3
Each chewable tablet contains approximately 0.93 mg fructose, approximately 0.10 mg phenylalanine (as a component of aspartame) and approximately 2.8 mg sorbitol.
Jedna tableta za žvakanje sadrži približno 0,93 mg fruktoze, približno 0,10 mg fenilalanina (kao sastavnice aspartama) i približno 2,8 mg sorbitola.
• Isentress granules for oral suspension are not recommended in pregnancy because they have not been studied in pregnant women.
• Primjena Isentress granula za oralnu suspenziju u trudnoći se ne preporučuje jer nije ispitana u trudnica.
In a comparison of 30 subjects with *28/*28 genotype to 27 subjects with wild-type genotype, the geometric mean ratio (90 % CI) of AUC was 1.41 (0.96, 2.09) and the geometric mean ratio of C12 hr was 1.91 (1.43, 2.55).
Usporedba 30 ispitanika s genotipom *28/*28 i 27 ispitanika s genotipom divljeg tipa pokazala je da geometrijska srednja vrijednost omjera (90% CI) AUC-a iznosi 1,41 (0,96; 2,09), a geometrijska srednja vrijednost omjera C12 h 1,91 (1,43; 2,55).
Injury, poisoning and procedural complications
Ozljede, trovanja i proceduralne komplikacije manje često slučajno predoziranje
Table 3 Pharmacokinetic Interaction Data in Adults
Tablica 3 Podaci o farmakokinetičkim interakcijama u odraslih
Raltegravir readily crossed the placenta in rats, but did not penetrate the brain to any appreciable extent.
Raltegravir s lakoćom prolazi kroz placentu štakorica, ali ne prodire u značajnijoj mjeri u mozak.
Administration of the chewable tablet with a high fat meal does not affect raltegravir pharmacokinetics to a clinically meaningful degree and the chewable tablet can be administered without regard to food.
Primjena tablete za žvakanje uz punomastan obrok ne utječe na farmakokinetiku raltegravira u klinički značajnoj mjeri te se tablete za žvakanje mogu uzimati neovisno o hrani.
0.7 mL (7 mg) once daily
0,7 ml (7 mg) jedanput na dan
No studies have been conducted to evaluate the drug interactions of ritonavir, tipranavir/ritonavir, boceprevir or etravirine with raltegravir 1,200 mg (2 x 600 mg) once daily.
Nisu provedena ispitivanja interakcija ritonavira, tipranavira/ritonavira, boceprevira ili etravirina s raltegravirom u dozi od 1200 mg (2 x 600 mg) jedanput na dan.
The effect of severe hepatic insufficiency on the pharmacokinetics of raltegravir has not been studied (see sections 4.2 and 4.4).
Učinak teške insuficijencije jetre na farmakokinetiku raltegravira nije ispitan (vidjeti dijelove 4.2 i 4.4).
Add the 10 mL of water to the mixing cup
5. korak: Dodajte odmjerenih 10 ml vode u čašu za miješanje
ISENTRESS chewable tablets can be administered with or without food (see section 5.2).
ISENTRESS tablete za žvakanje mogu se primjenjivati s hranom ili bez nje (vidjeti dio 5.2).
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.emea.europa.eu.
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
The doctor will tell you how much of the oral suspension the infant or toddler must take.
Liječnik će Vam reći koliko oralne suspenzije morate dati dojenčetu ili malom djetetu.
≤ 100,000 copies/mL CD4-count ≤ 200 cells/mm > 200 cells/mm Viral Subtype Clade B Non-Clade B 93.6 (89.1, 96.6) 93.2 (84.9, 97.8) 89.5 (84.1, 93.6) 94.4 (86.2, 98.4)
Početne karakteristike HIV-RNK > 100 000 kopija/ml ≤ 100 000 kopija/ml Broj CD4 stanica ≤ 200 stanica/mm > 200 stanica/mm Podtip virusa skupine B Podtipovi virusa osim skupine B 93,6 (89,1; 96,6) 93,2 (84,9; 97,8) 89,5 (84,1; 93,6) 94,4 (86,2; 98,4)
Uncommon palpitations, sinus bradycardia, ventricular extrasystoles
Srčani poremećaji manje često palpitacije, sinusna bradikardija, ventrikularne ekstrasistole
A carcinogenicity study of raltegravir in mice did not show any carcinogenic potential.
U ispitivanju kancerogenosti na miševima nije utvrđen kancerogeni potencijal raltegravira.
Get ready
1. korak: Pripremite se
Agents that increase gastric pH
Lijekovi koji povisuju želučani pH
In patients, after 1,200 mg once daily raltegravir dosing, steady state AUC0-24 was 53.7 h·μM, C24 was 75.6 nM, and median Tmax was 1.50 h.
Nakon primjene raltegravira u dozi od 1200 mg jedanput na dan, u bolesnika je AUC0-24 u stanju dinamičke ravnoteže iznosio 53,7 h·μM, C24 bio je 75,6 nM, a medijan Tmax 1,50 sati.
In treatment-naïve patients, the clinical study data on use of raltegravir are limited to use in combination with two nucleotide reverse transcriptase inhibitors (NRTIs) (emtricitabine and tenofovir disoproxil fumarate).
U bolesnika koji prethodno nisu bili liječeni podaci iz kliničkog ispitivanja primjene raltegravira ograničeni su na njegovu kombiniranu primjenu s dva nukleozidna inhibitora reverzne transkriptaze (engl. nucleotide reverse transcriptase inhibitors, NRTI) (emtricitabina i tenofovirdizoproksilfumarata).
2 white (1 mL) syringes
2 bijele (1 ml) štrcaljke
In these 96 children and adolescents, frequency, type and severity of drug related adverse reactions through Week 48 were comparable to those observed in adults.
U tih su 96 djece i adolescenata učestalost, vrsta i težina nuspojava povezanih s lijekom tijekom 48 tjedana bile usporedive s onima opaženima u odraslih.
Yellow, oval-shaped, dimensions 19.1 mm x 9.7 mm x 6.1 mm, marked with MSD corporate logo and “242” on one side and plain on the other side.
Žuta, ovalna tableta dimenzija 19,1 mm x 9,7 mm x 6,1 mm s logotipom tvrtke MSD i oznakom "242" na jednoj strani te bez oznaka na drugoj strani.
The active substance is raltegravir.
Djelatna tvar je raltegravir.
Put the tip of the syringe into the cup of the prepared Isentress and pull back on the plunger.
Uronite vrh štrcaljke u čašu s pripremljenim lijekom Isentress i počnite povlačiti klip.
Caution should be used when co-administering raltegravir with strong inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., rifampicin).
Potreban je oprez kod istodobne primjene raltegravira sa snažnim induktorima uridin difosfat glukuronoziltransferaze (UGT) 1A1 (npr. rifampicin).
There were no clinically important pharmacokinetic differences due to gender, race, ethnicity or body weight in adults for raltegravir 400 mg twice daily, and no clinically meaningful effect on raltegravir pharmacokinetics was concluded.
Nije bilo klinički važnih razlika u farmakokinetici lijeka s obzirom na spol, rasu, etničko podrijetlo i tjelesnu težinu u odraslih kod primjene raltegravira u dozi od 400 mg dvaput na dan te je zaključeno da ti parametri nemaju klinčki značajnog učinka na farmakokinetiku raltegravira.